GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Blood test may spare gastric cancer patients from unnecessary chemo
Disease control Not yet recruitingThis study tests whether a blood test that detects tiny traces of cancer DNA (ctDNA) can guide treatment after gastric cancer surgery. The goal is to see if patients with no detectable cancer DNA can safely skip additional chemotherapy, avoiding harsh side effects. About 90 adult…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated May 16, 2026 23:51 UTC
-
Stomach cancer shot could replace IV drip in major trial
Disease control Not yet recruitingThis study tests if an immunotherapy drug (AK104) given as a shot under the skin works as well as the same drug given through an IV drip, when both are combined with chemotherapy. About 422 people with advanced stomach or gastroesophageal junction cancer that cannot be removed by…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Engineered immune cells take on advanced stomach cancer in new trial
Disease control Not yet recruitingThis early-phase trial is testing a new treatment called CT0494BCP for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy uses specially engineered immune cells (CAR-T cells) designed to attack the…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug combo shows promise in shrinking stomach tumors before surgery
Disease control Not yet recruitingThis study tests a new drug called zanidatamab combined with chemotherapy before surgery for people with a specific type of stomach or gastroesophageal junction cancer that has high levels of HER2. About 30 adults with stage II or III cancer will receive the treatment to see if i…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New combo therapy targets tough gut cancers in major trial
Disease control Not yet recruitingThis study tests a new drug called SSGJ-706 combined with standard treatments for people with advanced stomach, colon, pancreatic, or esophageal cancers that cannot be removed by surgery. The goal is to see if the combination is safe and helps shrink or control tumors. About 300 …
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for Hard-to-Treat cancers: targeted combo therapy enters Mid-Stage trial
Disease control Not yet recruitingThis study tests a new drug called IBI343 combined with other treatments for people with advanced stomach, gastroesophageal junction, or pancreatic cancers that have a specific marker (CLDN18.2). The goal is to see if the combination is safe and shrinks tumors. About 389 adults w…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated May 06, 2026 16:13 UTC
-
Stomach cancer study seeks best Follow-Up care after complete response
Knowledge-focused Not yet recruitingThis study looks at 500 adults with stomach or gastroesophageal junction cancer who had surgery after chemotherapy and immunotherapy, and whose tumors were completely gone. Researchers want to see which post-surgery treatment plan works best to keep the cancer from coming back. P…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE4 • Sponsor: Liaoning Cancer Hospital & Institute • Aim: Knowledge-focused
Last updated May 04, 2026 16:22 UTC
-
Blood test may spare stomach cancer patients from unnecessary chemo
Knowledge-focused Not yet recruitingThis study looks at whether a blood test that detects tiny bits of tumor DNA (called ctDNA) can help doctors decide who needs extra chemotherapy after stomach cancer surgery. About 304 people with advanced stomach cancer will be randomly assigned to either standard care or treatm…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated May 04, 2026 16:19 UTC
-
Scientists investigate why some stomach cancers shrink with immunotherapy and others Don't
Knowledge-focused Not yet recruitingThis study looks at a specific type of stomach cancer (dMMR/MSI-H) that often responds well to immunotherapy, but about half of patients do not benefit. Researchers will treat 15 people with immunotherapy before surgery to see who has a complete response and study why some tumors…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Apr 26, 2026 19:39 UTC